Cognitive Decline Startup Advisory Board Member

We are seeking a highly accomplished executive, physician leader, or recognized thought leader in cognitive decline, brain health, or neurodegenerative disease to join our Advisory Board and provide strategic, governance level guidance to a high growth startup addressing one of healthcare's most urgent and rapidly expanding challenges.This role is designed for a senior leader who can help shape disciplined growth, clinical credibility, capital-efficient scaling, and long-term enterprise value creation in a complex, high visibility sector. The ideal candidate brings deep expertise in mild cognitive impairment (MCI), Alzheimer's disease, vascular cognitive impairment, and related neurodegenerative conditions, along with a strong understanding of how clinical innovation translates into scalable care models, reimbursement strategy, regulatory alignment, and durable market differentiation.As an Advisory Board Member, you will work closely with the CEO and executive leadership team to provide independent strategic counsel on clinical positioning, competitive differentiation, value-based care strategy, outcomes validation, regulatory considerations, and go-to-market execution. Your guidance will help ensure the company builds an evidence-based, operationally disciplined platform capable of delivering measurable clinical and economic outcomes while maintaining the highest standards of ethical care for cognitively vulnerable populations.From a governance perspective, you will offer objective oversight on strategic priorities, product roadmap alignment, risk mitigation, data integrity, and responsible innovation. You will help leadership balance ambitious growth with clinical rigor and regulatory prudence, ensuring expansion remains sustainable and aligned with long term stakeholder value.This is a rare opportunity to help shape a category-defining organization at the intersection of aging demographics, rising healthcare costs, neuroscience, and AI-enabled precision medicine. Your expertise will directly influence how the company strengthens investor confidence, builds defensible infrastructure, forms strategic partnerships, and drives meaningful impact in the cognitive health market.About Alzheimer's Treatment Centers of America (ATCA)Alzheimer's Treatment Centers of America (ATCA) leverages Artificial Intelligence (AI) and Personalized Precision Medicine to transform the treatment of Alzheimer's disease, dementia, and cognitive impairment, including brain fog associated with Long COVID.ATCA is focused on delivering structured, data-driven treatment to patients today. The model goes beyond traditional diagnosis to identify underlying contributors to neurodegeneration and cognitive dysfunction, then implements individualized treatment protocols designed to slow progression and improve functional outcomes.Our multidisciplinary leadership team includes experienced healthcare executives, neuroscientists, AI engineers, and clinical specialists working together to deploy a scalable, neurologist supported clinic model nationwide. As we expand, we are building a governance framework supported by senior physician leaders who understand clinical rigor, operational scalability, and health system integration.Why Now?Growing Community Need: Our Palm Beach Gardens/Jupiter clinic is fully operational and actively treating patients in a high-visibility medical corridor adjacent to Cleveland Clinic. Originally launched in a former urgent care space to enable rapid deployment, the clinic reached capacity quickly, with appointments booked months in advance, reflecting significant unmet demand for proactive cognitive care.Three additional clinics are in development, with broader national expansion underway. ATCA is building a repeatable, specialist-supported care model that expands access to structured cognitive evaluation and longitudinal management while maintaining clinical rigor and operational scalability.Seamless System Integration: ATCA's care model is designed to integrate within the existing healthcare ecosystem. Treatments are reimbursed by Medicare, Medicare Advantage, and most major commercial insurers, helping reduce barriers to access and accelerate patient adoption.Focused on Outcomes: In a study utilizing ATCA's AI-driven protocol, 75% of patients with mild cognitive impairment demonstrated no further cognitive decline. This reflects a proactive, data-driven approach that complements traditional management pathways and prioritizes measurable outcomes.Advanced Therapeutic Options: Eligible patients may have access to TB006, an FDA-approved therapy available for compassionate use, offering a potential treatment pathway for certain dementias, including Alzheimer's disease.Physician Supported: ATCA's protocols are supported by an experienced Medical Advisory Board of leading physicians and scientists. As we expand nationally, we are strengthening this advisory infrastructure with senior clinical leaders who bring expertise in governance, quality assurance, scalability, and system-based care delivery.Key AchievementsProprietary AI Precision Engine: ATCA has built and deployed a defensible AI driven precision medicine platform that optimizes Alzheimer's treatment at the individual patient level, creating meaningful clinical differentiation and long-term data network effects.High-Margin, Replicable Clinic Model: We have engineered a scalable specialty clinic platform targeting 44% EBITDA margins, supported by optimized staffing ratios, a high acuity service mix, and favorable reimbursement dynamics designed for rapid multi-market expansion.Massive, Underserved Market Opportunity: ATCA is positioned to capture share in a $355 billion U.S. Alzheimer's market and a $1.5 trillion global opportunity, addressing one of the largest and fastest-growing unmet needs in healthcare.Embedded Revenue-Generating Research Infrastructure: Each clinic integrates micro-research capabilities designed to generate real-world evidence, support pharmaceutical partnerships, enable clinical trial participation, and create recurring, high margin ancillary revenue streams.Responsibilities IncludeCognitive Health & Clinical Strategy :Provide advisory oversight on evidence-based cognitive decline models spanning early risk identification, screening, diagnosis, longitudinal management, and advanced care planning. Guide the development of clinically rigorous frameworks that improve cognitive and functional outcomes, enhance quality of life, reduce caregiver burden, and support measurable impact across diverse patient populations.Scalable Brain Health Platform Development: Advise on the design and scaling of interdisciplinary, technology-enabled, community integrated cognitive care solutions. Support the development of standardized yet adaptable care pathways that connect neurology, geriatrics, primary care, behavioral health, and caregiver services while maintaining scientific integrity and operational discipline.Value-Based & Reimbursement Strategy: Guide strategic positioning within Medicare Advantage, ACO, and other value-based reimbursement environments. Advise on outcomes validation, risk stratification, utilization management, quality reporting, documentation integrity, and payer alignment to support sustainable growth and defensible economic value.Governance & Enterprise Risk Oversight: Provide an independent, board-level perspective on strategic priorities, product roadmap alignment, regulatory exposure, data governance, clinical risk management, and ethical innovation in cognitively vulnerable populations. Help ensure responsible scaling, compliance alignment, and long-term stakeholder value creation.Executive & Growth Advisory: Partner with founders and executive leadership to align clinical and scientific strategy with product development, market differentiation, strategic partnerships, capital strategy, and investor communications. Support positioning that strengthens credibility with payers, providers, life sciences partners, and growth-stage investors.Innovation & Ecosystem Insight: Provide perspective on digital diagnostics, AI enabled cognitive assessment tools, remote monitoring, biomarker integration, and emerging therapeutic advances. Advise on evolving regulatory, reimbursement, and competitive dynamics across the broader cognitive health and neurodegenerative disease landscape.Why Join Us?Strategic Influence: Help shape the governance architecture of a rapidly expanding, AI enabled brain health platform.Board-Level Engagement: Contribute meaningfully at the advisory level without day to day operating responsibility.Impact at Scale: Support the responsible expansion of innovative cognitive care models while preserving the highest standards of clinical rigor and patient care.Enterprise Level Perspective: Apply your leadership experience to one of the most urgent and fastest-growing challenges in healthcare.Clinical Integrity During Innovation: Help safeguard accountability, quality, and patient safety as precision medicine platforms scale nationally.Compensation / PerksEquity Options: Receive stock options in recognition of your clinical leadership and advisory contributions to ATCA's mission.Investment Access: Select advisory board members may be offered access to ATCA's current financing round. Participation is optional and independent of the advisory role.Equal Opportunity CommitmentWe are committed to fostering inclusive advisory leadership. Diverse perspectives strengthen governance, innovation, and patient outcomes. Leaders from all backgrounds are encouraged to help shape the future of structured, scalable brain health care.